Conference Objectives
- Provide current and high-quality information on the latest developments in the management of lymphoproliferative disease
- Create collegial learning opportunities to enable clinicians to share real-world experience and to directly apply new insights to their practice
- Foster discussions that allow for the sharing of knowledge and experience among delegates and industry representatives
- Respond to emerging professional needs for specific and in-depth information on the latest therapies for lymphoproliferative disease in the Canadian market
Scientific Steering Committee
The scientific steering committee for the Toronto Lymphoma Conference 2024 includes Dr. John Kuruvilla and Dr. Peter Anglin.
John Kuruvilla, MD
Peter Anglin, MD
Conference Agenda
The Toronto Lymphoma Conference 2024 is a full day of in-person education and networking, with sessions on new and emerging innovations in treating and managing lymphoproliferative disease in Canada.
Time
Session
Speaker
7:45 am to 8:20 am
Community and Academic Perspectives on Navigating the Evolving Landscape of R/R DLBCL (Sponsored Breakfast Symposium, Incyte Biosciences Canada)
Samer Tabchi, MD
8:20 am to 8:25 am
Welcome and Opening Remarks
Peter Anglin, MD
8:25 am to 8:55 am
Managing older patients with HL
Joanna Rhodes, MD
8:55 am to 9:25 am
Primary CNS Lymphoma in 2024: Who should get what therapy?
Christopher Fox, MD
9:25 am to 9:55 am
Patient selection and bridging for CAR-T in aggressive B-cell lymphomas
Ivan Landego, MD
9:55 am to 10:10 am
HEALTH BREAK
ALL
10:10 am to 10:40 am
Post CAR T management in the community
Michael Jain, MD
10:40 am to 11:10 am
Bispecific Abs in aggressive B-cell lymphomas: a review of the current state
John Kuruvilla, MD
11:10 am to 11:40 am
CLL for the front line: many choices, what to do?
Graeme Fraser, MD
11:40 am to 12:00 pm
BUFFET LUNCH
ALL
12:00 pm to 12:45 pm
Targeting BTK for treatment of CLL: From inhibitors to degraders (Sponsored Lunch Symposium, BeiGene Canada)
Mazyar Shadman, MD
12:45 pm to 13:15 pm
Later lines/cellular therapy in CLL
Michael Jain, MD
13:15 pm to 13:45 pm
High grade and aggressive B-cell lymphoma: What is it and how to treat?
Michael Crump, MD
13:45 pm to 14:15 pm
CNS prophylaxis in DLBCL: the recommendations keep changing
Christopher Fox, MD
14:15 pm to 14:30 pm
HEALTH BREAK
ALL
14:30 pm to 15:00 pm
Follicular lymphoma at 1st and 2nd relapse: is there a standard?
Jon Friedberg, MD
15:00 pm to 15:30 pm
Current use of bispecific Abs in MM
Christine Chen, MD
15:30 pm to 16:00 pm
1st relapse of MM: Many choices
Sita Bhella, MD
16:00 pm to 16:30 pm
ct-DNA in Lymphoma: Moving diagnostics to the clinic
Robert Kridel, MD
16:30 pm to 16:35 pm
Closing Remarks & Adjournment
John Kuruvilla, MD
Our Sponsors
Key Sponsors
Leaders
Supporters
Single Meeting
Subscribe To Canadian Hematology Today
Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.
The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.
About Catalytic Health
Founded in 2009, Catalytic Health is one of Canada’s largest medical education agencies and reaches over 50,000 Canadian clinicians a year with its educational programs, services and platforms. Catalytic Health is also the largest independent medical publisher in Canada, one of the largest scientific conference providers, and a leader in innovative events and services for the Life Sciences industry. Learn more about Catalytic Health.
© 2024 All Rights Reserved.